Search clinical trials for: celecoxib, NPC, gefitinib

Total 386 results

China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Enzene Biosciences Ltd.
Alkem Laboratories Ltd

Recruiting

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

Healthy Male Subjects

Bulgaria, Poland
Rajesh Narendran
National Institute on Drug Abuse (NIDA)

Recruiting

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

Cocaine Use Disorder

United States
Guangdong Association of Clinical Trials

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (BELLA)

NSCLC

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Not yet recruiting

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Recruiting

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Locally Advanced or Metastatic NSCLC

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Guangdong Provincial People's Hospital

Not yet recruiting

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Advanced Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Qilu Pharmaceutical Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Chinese... and other collaborators

Not yet recruiting

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Lung Cancer

China
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
Sun Yat-sen University
Shenzhen People's Hospital; Sixth Affiliated Hospital, Sun Yat-sen University; Dongguan People's Hospital and other collaborators

Not yet recruiting

Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients

2-year Disease-Free Survival

China
University of Nebraska
National Cancer Institute (NCI)

Recruiting

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage IA Pancreatic Cancer AJCC v6 and v7 | Stage IB Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic... and other conditions

United States
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Sun Yat-sen University

Recruiting

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors

China
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Sun Yat-sen University
Wu Jieping Medical Foundation

Recruiting

Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Brain Metastases | EGFR Mutation

China
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Non-Small Cell Lung Cancer

United States
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
AstraZeneca

Active, not recruiting

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) (ORCHARD)

Non-Small Cell Lung Cancer

Denmark, Italy, Spain, United States, Korea, Republic of, Japan, Netherlands, Norway, Sweden
Eli Lilly and Company

Active, not recruiting

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (RELAY)

Metastatic Non-Small Cell Lung Cancer

France, Spain, United States, Italy, Canada, Taiwan, Hong Kong, Japan, Turkey, Korea, Republic of, United Kingdom, Germany, Romania, Greece
Intergroupe Francophone de Cancerologie Thoracique
AstraZeneca

Completed

Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature

Pneumonic-type Adenocarcinoma (P-ADC) | Lung Adenocarcinoma With Bronchiolo-alveolar Feature

France
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
M.D. Anderson Cancer Center
Takeda; Janssen Pharmaceuticals

Active, not recruiting

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

Recurrent Primary Amyloidosis | Refractory Primary Amyloidosis | Newly Diagnosed Primary Amyloidosis

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
University of Chicago

Completed

A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma

Head and Neck Cancer

United States
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
University of Nebraska
National Cancer Institute (NCI)

Terminated

Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone Therapy

Prostate Cancer

United States
Beta Pharma Shanghai

Active, not recruiting

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

NSCLC

China
NCIC Clinical Trials Group

Terminated

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Bladder Cancer

Canada
RenJi Hospital

Completed

Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

Hepatocellular Carcinoma | Molecular Targeted Therapy

China
Fudan University

Completed

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Non-small-cell Lung Cancer

China
Massachusetts General Hospital
Novartis

Active, not recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Boehringer Ingelheim

Completed

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib (UpSwinG)

Non-squamous, Non-Small Cell Lung Cancer

United Kingdom
University of Chicago

Completed

Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer

Head and Neck Cancer

United States
National Cancer Centre, Singapore
Novartis

Completed

A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR (BKM120)

Non-Small Cell Lung Cancer | Solid Tumors

Singapore
Assistance Publique Hopitaux De Marseille

Completed

A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing soliD Tumours. (SFCE METRO 01)

Survival Without Progression

France
Daiichi Sankyo Co., Ltd.

Terminated

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Japan
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Active, not recruiting

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Non Small Cell Lung Cancer

China
Alpha Biopharma (Jiangsu) Co., Ltd.

Completed

First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases (BM)

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

China, Korea, Republic of, Singapore, Taiwan
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)

Non-small Cell Lung Carcinoma
Merck KGaA, Darmstadt, Germany

Completed

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Non-small Cell Lung Cancer

Spain, Taiwan, Korea, Republic of, Singapore, China, Malaysia, Italy
European Organisation for Research and Treatment...
AstraZeneca

Active, not recruiting

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) (APPLE)

NSCLC

France, Spain, Slovenia, Jordan, Poland
Sunshine Lake Pharma Co., Ltd.

Active, not recruiting

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Non-small Cell Lung Cancer

China
Samsung Medical Center

Completed

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Stomach Neoplasms

Korea, Republic of
Samsung Medical Center

Completed

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

Solid Tumor

Korea, Republic of
London School of Hygiene and Tropical Medicine

Completed

Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2) (NECTAR2)

Malaria, Falciparum

Mali
Kadmon Corporation, LLC

Completed

Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib

Carcinoma, Non-Small-Cell Lung

United States

Search clinical trials for: celecoxib, NPC, gefitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations